India commands 40 per cent of global capacity for vaccines which is estimated at 5.7 billion doses
From auto firms planning new launches for festive season, Rajnath Singh banning import of defence items to telcos awaiting SC response of AGR dues, here are the top ness of the day
Asserts safety and quality are important and that his firm will develop a vaccine that's affordable for all
With the studies entering human trial phase, a critical requirement is to select volunteers who are willing to participate
The healthy volunteers, who were administered the first dose of the vaccine in the morning, were stable.
Covaxin is being tested in 12 places, according to the Indian Council for Medical Research.
Bharat Biotech got the country's drug regulator's approval to start clinical trials of its anti-Corona vaccine Covaxin recently
India's challenge immense in coronavirus crisis immense because of its large population, says billionaire philanthropist
Under normal circumstances, the development of new vaccines and treatments could take 10-20 years
Sites may end with varying timelines based on site initiation visit by Bharat Biotech
Sites may end with varying timeline based on site initiation visit by Bharat Biotech
Bharat Biotech had recently received a nod for a clinical trial of its vaccine - Covaxin
The article has been published on the websites of the Press Information Bureau (PIB) and the Vigyan Prasar, which is a body under the ministry
Along with the two Indian efforts, the world over, 11 out of 140 vaccine candidates have entered the human trial phase
On Thursday, CDSCO also approved Zydus Cadila's plasmid DNA vaccine candidate ZyCoV-D, developed at its Vaccine Technology Centre in Ahmedabad.
A total of 12 institutes have been asked by the ICMR to fast track clinical trials of the vaccine as it is being considered the topmost priority projects which are being monitored by the government
India reported nearly 21,000 coronavirus cases in the last 24 hours, taking the total to 625,544, according to the Health Ministry.
Indigenously developed Bharat Biotech's vaccine candidate Covaxin is entering human trials on Wednesday.
The SARS-CoV-2 strain was isolated at National Institute of Virology (Pune), an institute under the ICMR, and transferred to Bharat Biotech.
The second of a two-part series examines challenges linked to IPR and monopoly once Covid-19 vaccine is created